News Releases

Below are the latest News Releases for Clearmind Medicine Inc.

6

January

2025

Clearmind Medicine Announces the Publication of European Patent Application for Binge Behavior Psychedelic Combination Treatment
Read More
2

January

2025

Clearmind Medicine Granted Patent for Binge Behavior Treatment by the Macau International Intellectual Property Office
Read More
24

December

2024

Clearmind Medicine Receives IRB Approval for its FDA-Regulated Clinical Trial
Read More
16

December

2024

Clearmind Medicine and Dr Glitter Pty Ltd Sign Term Sheet for Mutual Development of Novel Psychedelic MEAI- Based Alcohol (...)
Read More
10

October

2024

Clearmind Medicine Announces IRB Approval for FDA First-In-Human Clinical Trial of CMND-100 at Second Clinical Site
Read More
16

September

2024

Clearmind Medicine Announces the Notice of an International Patent Application for Pioneering Ibogaine Combination Therapy
Read More
12

September

2024

Clearmind Medicine and Yissum File International Patent Application for Revolutionary Psychedelic Compounds for PTSD Treatment
Read More
6

September

2024

Clearmind Medicine Announces Publication of International Patent Application for Innovative MDMA-Based Combination Treatment
Read More
29

August

2024

Clearmind Medicine Announces Publication of its Patent Application for Innovative Ketamine-Based Combination Treatment
Read More
21

August

2024

Clearmind Medicine Granted U.S. Patent Approval for Binge Behavior Treatment
Read More
16

August

2024

Clearmind Medicine and Yissum Expand Collaboration with International Patent Application for Generation 3.0 Psychedelic Compounds
Read More
6

August

2024

Clearmind Medicine: New Scientific Publication Shows MEAI's Potential as a Novel Weight Loss Drug
Read More
31

July

2024

Clearmind Medicine Concludes the Successful Participation in the Psychedelic Medicine – Israel 2024 Conference
Read More
19

July

2024

Clearmind Medicine Signs an Agreement to Source Manufacturers and Distributors for its Alcohol Substitute Beverage Product
Read More
16

July

2024

Clearmind Obtains IND Approval from the FDA to Start Phase I/IIa Clinical Trial with its Innovative Treatment for Alcoholism
Read More